140 related articles for article (PubMed ID: 11602824)
21. Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP.
Hanson MS; Stephenson AH; Bowles EA; Sridharan M; Adderley S; Sprague RS
Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H786-93. PubMed ID: 18586889
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory action of cilostazol, a phosphodiesterase III inhibitor, on catecholamine secretion from cultured bovine adrenal chromaffin cells.
Azuma M; Houchi H; Mizuta M; Kinoshita M; Teraoka K; Minakuchi K
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S29-32. PubMed ID: 12688393
[TBL] [Abstract][Full Text] [Related]
23. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow.
Birk S; Kruuse C; Petersen KA; Jonassen O; Tfelt-Hansen P; Olesen J
J Cereb Blood Flow Metab; 2004 Dec; 24(12):1352-8. PubMed ID: 15625409
[TBL] [Abstract][Full Text] [Related]
24. Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit.
Shiraishi Y; Kanmura Y; Itoh T
Br J Pharmacol; 1998 Mar; 123(5):869-78. PubMed ID: 9535015
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Birk S; Edvinsson L; Olesen J; Kruuse C
Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
[TBL] [Abstract][Full Text] [Related]
26. New inotropic agents: milrinone analogs.
Dorigo P; Fraccarollo D; Gaion RM; Santostasi G; Borea PA; Floreani M; Mosti L; Maragno I
Gen Pharmacol; 1997 May; 28(5):781-8. PubMed ID: 9184820
[TBL] [Abstract][Full Text] [Related]
27. Cilostazol as a unique antithrombotic agent.
Kambayashi J; Liu Y; Sun B; Shakur Y; Yoshitake M; Czerwiec F
Curr Pharm Des; 2003; 9(28):2289-302. PubMed ID: 14529391
[TBL] [Abstract][Full Text] [Related]
28. Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3).
Baek AE; Kanthi Y; Sutton NR; Liao H; Pinsky DJ
FASEB J; 2013 Nov; 27(11):4419-28. PubMed ID: 23901069
[TBL] [Abstract][Full Text] [Related]
29. Effects of milrinone on contractility and cyclic adenosine monophosphate production induced by beta1- and beta2-adrenergic receptor activation in human myocardium.
Carceles MD; Fuentes T; Aroca V; Lopez J; Hernández J
Clin Ther; 2007 Aug; 29(8):1718-24. PubMed ID: 17919552
[TBL] [Abstract][Full Text] [Related]
30. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects.
Hirose H; Mashiko S; Kimura T; Ishida F; Mochizuki N; Nishibe T; Nishikibe M
J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790
[TBL] [Abstract][Full Text] [Related]
31. Interplay between milrinone and adenosine in the inhibition of human platelet response.
Anfossi G; Massucco P; Piretto V; Mularoni E; Cavalot F; Mattiello L; Trovati M
Gen Pharmacol; 1996 Oct; 27(7):1149-54. PubMed ID: 8981060
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
Ikeda Y
Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
[No Abstract] [Full Text] [Related]
33. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Sudo T; Tachibana K; Toga K; Tochizawa S; Inoue Y; Kimura Y; Hidaka H
Biochem Pharmacol; 2000 Feb; 59(4):347-56. PubMed ID: 10644042
[TBL] [Abstract][Full Text] [Related]
34. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
35. Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and 45Ca2+ uptake by human platelets.
Jeremy JY; Gill J; Mikhailidis D
Eur J Pharmacol; 1993 Mar; 245(1):67-73. PubMed ID: 7682964
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
37. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
38. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta.
Nakamura T; Houchi H; Minami A; Sakamoto S; Tsuchiya K; Niwa Y; Minakuchi K; Nakaya Y
Life Sci; 2001 Aug; 69(15):1709-15. PubMed ID: 11665832
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase III inhibition affects platelet-monocyte aggregate formation depending on the axis of stimulation.
Horn NA; Anastase DM; Hecker KE; Baumert JH; Scheffer GJ; Rossaint R
J Cardiothorac Vasc Anesth; 2006 Apr; 20(2):162-6. PubMed ID: 16616654
[TBL] [Abstract][Full Text] [Related]
40. Negative functional effects of cyclic GMP are altered by cyclic AMP phosphodiesterases in rabbit cardiac myocytes.
Weiss HR; Lazar MJ; Punjabi K; Tse J; Scholz PM
Eur J Pharmacol; 2003 Nov; 481(1):25-31. PubMed ID: 14637171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
